Pierre Fabre and the EspeRare Foundation administer investigational treatment to first patient in EDELIFE clinical trial for rare genetic disease, XLHED
The EspeRare Foundation and Pierre Fabre join forces to develop and market a pioneering treatment for XLHED, a dermatologic-related rare genetic disease that requires prenatal therapeutic intervention
Have a beautiful skin with our 8 expert brands | Pierre Fabre
Have a beautiful skin with our 8 expert brands | Pierre Fabre
Pierre Fabre Oral Care : soins et hygiène bucco-dentaire | E.Leclerc
Pierre Fabre Company Profile: Valuation & Investors | PitchBook
Olivier Delannoy on LinkedIn: Discover the Pierre Fabre and its brands
Pierre Fabre is taking a minority stake in Gennisium Pharma
Stade Pierre Fabre Castres - Pop And Kop
Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets
T-shirt Pierre Fabre Castres
Have a beautiful skin with our 8 expert brands | Pierre Fabre
EspeRare Partners with Pierre Fabre to Develop Treatment for XLHED - NFED
Pierre Fabre and the EspeRare Foundation administer investigational treatment to first patient in EDELIFE clinical trial for rare genetic disease, XLHED
Sweat à capuche - Rugby - Castres - Hémisphère Nord
Pierre Fabre is supporting “Les Bacchantes”;
Sweat à capuche - Rugby - Castres - Hémisphère Nord
EspeRare partners its XLHED program with Pierre Fabre | EspeRare Foundation
Olivier Delannoy on LinkedIn: Discover the Pierre Fabre and its brands
